AMENDMENTS TO THE CLAIMS

1. (Currently amended) A recombinant herpes simplex virus (HSV) particle having at least one protein on its surface, comprising: (a) an altered viral surface protein, wherein the alteration reduces binding of the viral surface protein to a sulfated proteoglycan; (b) an altered gD, wherein the alteration reduces binding of gD to one or more of its cellular receptors; and (c) a heterologous peptide ligand on the surface of the recombinant HSV particle, the heterologous peptide ligand forming a fusion protein with the altered gD, whereby the HSV particle exhibits specific affinity for a cell surface component that is not a natural viral receptor.

2. (Currently amended) The recombinant HSV particle of claim 1, wherein the viral surface protein is selected from the group consisting of gB and gC.

3. (Canceled)

4. (Currently amended) The recombinant HSV particle of claim 1, wherein the alteration of gD reduces binding to HveA or HveC.

5. (Canceled)

6. (Currently amended) The recombinant HSV particle of claim 1, wherein the ligand forms a second fusion protein with a viral surface protein selected from the group consisting of gB and gC.

7. (Canceled)

8. (Original) The recombinant HSV particle of claim 1, wherein the ligand binds a receptor on the surface of a cell.

9. (Original) The recombinant HSV particle of claim 8, wherein the cell is a cancer cell.

10. (Original) The recombinant HSV particle of claim 9, wherein the cancer cell is a tumor cell.

11. (Original) The recombinant HSV particle of claim 9, wherein the cancer cell is a malignant gliomal cell.

12. (Original) The recombinant HSV particle of claim 1, wherein the ligand is a cytokine.

13. (Original) The recombinant HSV particle of claim 12, wherein the cytokine is IL13.

14. (Original) The recombinant HSV particle of claim 1, the ligand is a single-chain antibody.

15. (Original) A method of targeting a recombinant HSV particle to a cell comprising creating an HSV comprising a peptide ligand to a surface receptor specific to the cell, wherein the peptide ligand forms a fusion protein with an altered gD.

16. (Currently amended) The method of claim 15, further comprising altering a viral surface protein[[,]] selected from the group consisting of gB and gC, wherein the alteration reduces binding of the viral surface protein to a sulfated proteoglycan.

17.-18. (Canceled)

19. (Currently amended) The method of claim 15, wherein the alteration to gD reduces binding of gD to at least one natural cellular receptor for gD.

20. (Currently amended) The method of claim 19, wherein the alteration of gD reduces binding to HveA or HveC.

21. (Canceled)

22. (Currently amended) The method of claim 15 ~~21~~, wherein the ligand forms a fusion protein with gC.

23. (Original) The method of claim 15, wherein the cell is a cancer cell.

24.-25. (Canceled)

26. (Original) The method of claim 15, wherein the ligand is a cytokine.

27.-34. (Canceled)

35. (Original) A method of killing a target cell, comprising contacting the target cell with a recombinant HSV particle, wherein the HSV particle comprises an altered gD forming a fusion with a peptide ligand to a receptor specific to the cell.

36.-49. (Canceled)